Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28173828 | 1.00 | ACACB (0.36) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL17574380 | 0.91 | ALDH1A1 (0.36) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL7299678 | 0.91 | ALDH1A1 (0.36) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL9073870 | 0.91 | ALDH1A1 (0.36) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL17558184 | 0.90 | ACACB (0.38) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL17558186 | 0.90 | ACACB (0.38) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL13519732 | 0.89 | ALDH1A1 (0.36) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL15080558 | 0.89 | ALDH1A1 (0.36) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL9214882 | 0.87 | KDM4E (0.36) | ACACBACACAALDH1A1KMT2AMEN1 | |
| SCHEMBL9214872 | 0.87 | KDM4E (0.36) | ACACBACACAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283403-A1 | DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2016036893-A1 | DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283403-A1 | DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS | TFPI, TFPI2, F2 | ACACB 3280/4885ACACA 2699/4885ALDH1A1 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.